Latest news with #HardikParikh
Yahoo
18-04-2025
- Business
- Yahoo
JPMorgan says Lilly data ‘highly favorable' for Structure Therapeutics
JPMorgan analyst Hardik Parikh says Eli Lilly's (LLY) Phase 3 data for orforglipron in type 2 diabetes suggest a 'highly competitive profile' for the drug. The firm views the data as its base case scenario, whereby Structure Therapeutics (GPCR) shares could be up double-digit percent in this scenario on a 'highly favorable read-through' and Viking Therapeutics (VKTX) could move mid-single-digit in either direction. JPMorgan's focus was primarily on orfoglipron's tolerability profile with the extended titration, and here the data is highlighted by an 8% discontinuation rate on the highest dose versus low-teens expectations, the analyst tells investors in a research note. The firm sees the data as 'helping derisk the category,' giving more confidence that Structure can also bring tolerability of aleniglipron to reasonable levels. For Viking, the read-through is not as direct, and today's data 'clearly helps derisk a strong' first in class oral competitor from Lilly, which could limit the potential of late entrant injectable assets, says JPMorgan. However, the firm believes the data 'still leaves a clear role' for Viking's 'highly tolerable' oral VK-2735. Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on GPCR: Disclaimer & DisclosureReport an Issue Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill JPMorgan says Pfizer news 'mostly a positive' for Structure, Viking Viking, Structure rally after Pfizer halts obesity drug development Pfizer Stock (PFE) Dips after Weight-Loss Pill Halted Over Liver Injury Structure Therapeutics, Inc.: Strong Pipeline and Financial Stability Underpin Buy Rating Despite Price Target Reduction
Yahoo
12-03-2025
- Business
- Yahoo
Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo Nordisk stock slides 4%
Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma (ZLDPF), the companies announced Wednesday. The deal would give Zealand a partner to co-develop petrelintide, an amylin therapy, as a new anti-obesity drug. The drug is currently in phase II trials. Amylin therapies are considered the next generation of obesity medication from the current GLP-1 products sold by Danish drug giant Novo Nordisk (NVO) and Eli Lilly (LLY). Novo's stock slid earlier this week on news that CargriSema, its combination therapy using the GLP-1 semaglutide and the amylin cagrilintide, didn't have a significantly higher weight-loss result than the current market products. The deal with Zealand includes a standalone treatment as well as exploring a combination product with Roche's GLP-1 candidate, which is still in its clinical phase. Roche is paying Zealand $1.65 billion upfront of which $1.4 billion will be paid after the deal closes. The remainder will be paid out over the next few years. The news sent Roche's stock up more than 4% in trading Wednesday, and Zealand's stock skyrocketed 40% on the news. Meanwhile, Novo Nordisk's stock was hit, sliding 4%, and Eli Lilly's stock was down just under 1%. The impact to Novo's stock is largely due to the CagriSema news earlier this week, along with the increased competition in the amylin space. Lilly, meanwhile, is focused on changing the game with a weight-loss pill, so its stock was less affected. Mizuho Securities healthcare sector expert Jared Holz noted that Novo will need to take "proactive [measures] to get ahead of various pricing dynamics — both in terms of the IRA and patent expiry. Needs an oral option no doubt — that will likely remain the focus for investors over the next couple of quarters." JPMorgan analyst Hardik Parikh wrote in a note to clients Wednesday that the deal adds to Roche's efforts in the obesity space and that the next-gen amylin space is likely to heat up. "Roche had already acquired Carmot in early 2024 for $3 billion and we could see other pharma companies taking multiple shots on goal in this space with multiple MOAs. And as evidenced by ABBV's [AbbVie's] partnership with Gubra (also an amylin analog) earlier this month, we see a broad group of companies interested including those who don't historically have a major foot print in the cardiometabolic space," Parikh wrote. Investors are waiting to see how Zealand's products compete in the obesity drug space, which has seen as much as 24% weight loss — a bar set by Lilly's products — become the norm. Jefferies analysts wrote in a note Wednesday that Zealand's drug is already proving more potent than Novo's in smaller doses, but only late-stage trials will provide clarity on effectiveness and side effects and give investors a chance to better compare the products. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Sign in to access your portfolio
Yahoo
12-03-2025
- Business
- Yahoo
Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo stock slides 4%
Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma (ZLDPF), the companies announced Wednesday. The deal would give Zealand a partner to co-develop petrelintide, an amylin therapy, as a new anti-obesity drug. The drug is currently in Phase 2 trials. Amylin therapies are considered the next generation of obesity medication from the current GLP-1 products sold by Danish drug giant Novo Nordisk (NVO) and Eli Lilly (LLY). Novo's stock slid earlier this week on news that CargriSema, its combination therapy using the GLP-1 semaglutide and the amylin cagrilintide, didn't have a significantly higher weight-loss result than the current market products. The deal with Zealand includes a standalone treatment as well as exploring a combination product with Roche's GLP-1 candidate, which is still in its clinical phase. Roche is paying Zealand $1.65 billion upfront and $1.4 billion after the deal closes. The remainder will be paid out over the next few years. The news sent Roche's stock up more than 4% in trading Wednesday, and Zealand's stock skyrocketed 40% on the news. Meanwhile, Novo Nordisk's stock was hit, sliding 4%, and Eli Lilly's stock was down just under 1%. The impact to Novo's stock is largely due to the CagriSema news earlier this week, along with the increased competition in the amylin space. Lilly, meanwhile, is focused on changing the game with a weight-loss pill, so its stock was less affected. Mizuho Securities healthcare sector expert Jared Holz noted that Novo will need to take "proactive [measures] to get ahead of various pricing dynamics — both in terms of the IRA and patent expiry. Needs an oral option no doubt — that will likely remain the focus for investors over the next couple of quarters." JPM analyst Hardik Parikh wrote in a note to clients Wednesday that the deal adds to Roche's efforts in the obesity space and that the next-gen amylin space is likely to heat up. "Roche had already acquired Carmot in early 2024 for $3 billion and we could see other pharma companies taking multiple shots on goal in this space with multiple MOAs. And as evidenced by ABBV's [AbbVie's] partnership with Gubra (also an amylin analog) earlier this month, we see a broad group of companies interested including those who don't historically have a major foot print in the cardiometabolic space," Parikh wrote. Investors are waiting to see how Zealand's products compete in the obesity drug space, which has seen as much as 24% weight loss — a bar set by Lilly's products — become the norm. Jefferies analysts wrote in a note Wednesday that Zealand's drug is already proving more potent than Novo's in smaller doses, but only late-stage trials will provide clarity on effectiveness and side effects and give investors a chance to better compare the products. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Sign in to access your portfolio
